Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Conjupro Biotherapeutics, Inc.
Filamon LTD
Atavistik Bio, Inc
PMV Pharmaceuticals, Inc
AstraZeneca
University of Michigan Rogel Cancer Center
Alterome Therapeutics, Inc.
Rutgers, The State University of New Jersey
Eli Lilly and Company
BeOne Medicines
Monte Rosa Therapeutics, Inc
Psyence Australia Pty Ltd
ViroMissile, Inc.
University of Virginia
Dana-Farber Cancer Institute
Case Comprehensive Cancer Center
Novartis
Duke University
University of Florida
AstraZeneca
Tizona Therapeutics, Inc
University of Florida
Essen Biotech
Essen Biotech
Leiden University Medical Center
Clasp Therapeutics, Inc.
Columbia University
Eli Lilly and Company
Angiex, Inc.
Sapience Therapeutics
IDEAYA Biosciences
Ottawa Hospital Research Institute
Memorial Sloan Kettering Cancer Center
University of Colorado, Denver
Centre Paul Strauss
Unity Health Toronto
Mälardalen University
Daiichi Sankyo
University of Maryland, Baltimore
Memorial Sloan Kettering Cancer Center
Case Comprehensive Cancer Center
Guerbet
Eli Lilly and Company
Oscotec Inc.
Dana-Farber Cancer Institute
University of Michigan Rogel Cancer Center
Kidney Cancer Research Bureau